Capricor Therapeutics, Inc. , a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has completed enrollment of its first Phase II clinical trial of Cenderitide in ambulatory heart failure patients. Cenderitide is in development for the outpatient treatment of patients following an acute admission for heart failure, as well as other potential indications.
http://ift.tt/1Ex4che
http://ift.tt/1Ex4che
No comments:
Post a Comment